https://www.palvellatx.com/2023/01/05/palvella-therapeutics-announces-series-d-financing-of-up-to-37-7-million/ 2023-01-05T22:00:42+00:00 https://www.palvellatx.com/2023/02/21/palvella-therapeutics-announces-pipeline-update-on-qtorin-rapamycin/ 2023-02-21T16:12:53+00:00 https://www.palvellatx.com/2023/03/09/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-for-the-treatment-of-microcystic-lymphatic-malformations/ 2023-03-22T13:29:38+00:00 https://www.palvellatx.com/2023/07/20/palvella-therapeutics-reports-topline-results-from-pivotal-phase-3-vapaus-study-of-qtorin-rapamycin-pachyonychia-congenita/ 2023-07-25T21:35:37+00:00 https://www.palvellatx.com/2024/07/24/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement/ 2024-07-24T19:04:57+00:00 https://www.palvellatx.com/2023/11/16/fda-breakthrough-therapy-designation-qtorin-rapamycin-microcystic-lymphatic-malformations/ 2024-07-24T19:05:21+00:00 https://www.palvellatx.com/2023/07/20/palvella-therapeutics-announces-planned-pivotal-phase-3-study-design-of-qtorin-rapamycin-microcystic-lymphatic-malformations/ 2024-07-24T19:05:27+00:00 https://www.palvellatx.com/wp-content/uploads/2023/07/mlm-data.png https://www.palvellatx.com/2024/10/03/palvella-therapeutics-awarded-up-to-2-6-million-grant/ 2024-10-03T11:37:07+00:00 https://www.palvellatx.com/2024/10/15/palvella-therapeutics-announces-presentations-at-the-12th-pediatric-dermatology-research-alliance-annual-conference/ 2024-10-15T11:34:37+00:00 https://www.palvellatx.com/2024/10/17/palvella-therapeutics-appoints-matthew-e-korenberg-as-chief-financial-officer/ 2024-10-17T11:35:50+00:00 https://www.palvellatx.com/2024/11/07/palvella-therapeutics-announces-first-patient-dosed-in-phase-3/ 2024-11-07T13:52:37+00:00 https://www.palvellatx.com/2025/06/23/pulmonary-delivery-of-prs-400-anti-jagged-1-anticalin-proteins-reduce-inflammation-driven-goblet-cell-metaplasia-and-mucus-hypersecretion-in-vivo/ 2025-06-25T02:25:37+00:00 https://www.palvellatx.com/2025/06/23/preclinical-profile-of-prs-220-a-novel-inhaled-inhibitor-of-ctgf-ccn2-in-clinical-development-for-idiopathic-pulmonary-fibrosis/ 2025-06-25T02:25:59+00:00 https://www.palvellatx.com/2025/06/23/combination-of-cinrebafusp-alfa-with-ramucirumab-and-paclitaxel-is-well-tolerated-and-elicits-encouraging-clinical-activity-in-patients-with-her2-positive-gastric-gastroesophageal-junction-gej-adeno/ 2025-06-25T02:26:08+00:00 https://www.palvellatx.com/2025/06/23/development-of-prs-400-an-inhaled-jagged-1-specific-anticalin-protein-for-the-treatment-of-muco-obstructive-lung-diseases-ers-2022/ 2025-06-25T02:26:14+00:00 https://www.palvellatx.com/2025/06/23/prs-220-a-novel-inhalable-therapeutic-intervention-for-ipf-targeting-ctgf-directly-in-the-lung-ats-2022/ 2025-06-25T02:26:25+00:00 https://www.palvellatx.com/2025/06/23/the-anticalin-antibody-bispecific-prs-352-s095025-strongly-stimulates-human-cd4-t-cells-in-a-pd-l1-dependent-manner-aacr-2022/ 2025-06-25T02:26:34+00:00 https://www.palvellatx.com/2025/06/23/development-of-prs-220-a-potential-best-in-class-inhaled-ctgf-ccn2-inhibitor-for-the-treatment-of-ipf-ers-2022/ 2025-06-25T02:26:46+00:00 https://www.palvellatx.com/2025/06/23/phase-1-dose-escalation-study-of-prs-343-a-her2-4-1bb-bispecific-molecule-in-patients-with-her2-malignancies-aacr-2021/ 2025-06-25T02:26:53+00:00 https://www.palvellatx.com/2025/06/23/a-phase-1-dose-escalation-study-of-prs-343-a-her2-4-1bb-bispecific-molecule-in-patients-with-her2-positive-malignancies-esmo-2020/ 2025-06-25T02:27:09+00:00 https://www.palvellatx.com/2025/06/23/phase-1-dose-escalation-study-of-prs-343-a-her2-4-1bb-bispecific-molecule-in-patients-with-her2-malignancies-sitc-2019/ 2025-06-25T02:27:18+00:00 https://www.palvellatx.com/2025/06/23/bruns-ib-fitzgerald-mf-pardali-k-gardiner-p-keeling-dj-axelsson-lt-jiang-f-lickliter-j-close-dr5-phase-1-evaluation-of-the-inhaled-il-4r%ce%b1-antagonist-azd1402-prs-060-a-potent-and-selecti/ 2025-06-25T02:27:25+00:00 https://www.palvellatx.com/2025/06/23/bruns-ib-fitzgerald-mf-mensing-g-tsung-m-pardali-k-gardiner-p-keeling-dj-axelsson-lt-olsson-m-ghobadi-c-walsh-o-mclendon-k-farinola-n-hatchuel-l-close-dr-multiple-ascending-dose-study-o/ 2025-06-25T02:27:33+00:00 https://www.palvellatx.com/2025/06/23/multiple-ascending-dose-study-of-the-inhaled-il-4r%ce%b1-antagonist-azd1402-prs-060-in-mild-asthmatics-demonstrates-robust-feno-reduction-and-a-promising-clinical-profile-for-the-treatment-of-asthma/ 2025-06-25T02:27:57+00:00 https://www.palvellatx.com/2025/06/23/bruns-ib-fitzgerald-mf-pardali-k-gardiner-p-keeling-dj-axelsson-lt-jiang-f-lickliter-j-close-dr-first-in-human-data-for-the-inhaled-il-4r%ce%b1-antagonist-azd1402-prs-060-reveals-a-promising/ 2025-06-25T02:28:08+00:00 https://www.palvellatx.com/2025/06/23/birgit-bossenmaier-corinna-schlosser-rachida-siham-bel-aiba-eva-maria-hansbauer-thomas-jaquin-christian-barthels-janet-peper-markus-zettl-benjamin-weiche-thibaut-angevin-michelle-yegres-ren/ 2025-06-25T02:28:17+00:00 https://www.palvellatx.com/2025/06/23/katerina-pardali-fanyi-jiang-mary-fitzgerald-gabriele-matschiner-david-keeling-azd1402-prs-060-an-inhaled-anticalin-il-4ra-antagonist-potently-inhibits-il-4-induced-functional-effects-in-human/ 2025-06-25T02:28:34+00:00 https://www.palvellatx.com/2025/06/23/marlon-j-hinner-rachida-siham-bel-aiba-thomas-jaquin-sven-berger-manuela-durr-corinna-schlosser-andrea-allersdorfer-christine-rothe-louis-a-matis-shane-a-olwill-preclinical-toxicology-and/ 2025-06-25T02:28:49+00:00 https://www.palvellatx.com/2025/06/23/g-matschiner-s-huang-s-constant-b-rattenstetter-h-gille-a-m-hohlbaum-b-h-koller-d-keeling-m-fitzgerald-2018-the-discovery-and-development-of-azd1402-prs-060-a-potent-and-selective/ 2025-06-25T02:29:28+00:00 https://www.palvellatx.com/2025/06/23/lutz-renders-frank-dellanna-frantisek-svara-jitka-rehorova-ondrej-viklicky-ming-wen-matthias-braunisch-karoline-meurer-anne-maschek-goran-martic-kayti-aviano-louis-matis-ingmar-bruns-a-ph/ 2025-06-25T02:29:36+00:00 https://www.palvellatx.com/2025/06/23/lutz-renders-ming-wen-frank-dellanna-sven-heinrichs-klemens-budde-christian-rosenberger-christiane-erleybirgit-bader-claudia-sommerer-schaier-matthias-werner-feuerer-edgar-fenzl-rachel-va/ 2025-06-25T02:29:46+00:00 https://www.palvellatx.com/2025/06/23/hendrik-gille-martin-hulsmeyer-stefan-trentmann-gabriele-matschiner-hans-jurgen-christian-todd-meyer-ali-amirkhosravi-laurent-p-audoly-andreas-m-hohlbaum-arne-skerra-2015-functional-chara/ 2025-06-25T02:30:10+00:00 https://www.palvellatx.com/2025/06/23/marlon-j-hinner-rachida-siham-bel-aiba-alexander-wiedenmann-corinna-schlosser-andrea-allersdorfer-gabriele-matschiner-christine-rothe-ulrich-moebius-shane-a-olwill-cri-2015-poster-presentat/ 2025-06-25T02:30:19+00:00 https://www.palvellatx.com/2025/06/23/terwisscha-van-scheltinga-ag-lub-de-hooge-mn-hinner-mj-verheijen-rb-allersdorfer-a-hulsmeyer-m-nagengast-wb-schroder-cp-kosterink-jg-de-vries-eg-audoly-l-olwill-sa-2014-in-vivo-visualizat/ 2025-06-25T02:30:28+00:00 https://www.palvellatx.com/2025/06/23/gebauer-m-schiefner-a-matschiner-g-skerra-a-2013-combinatorial-design-of-an-anticalin-directed-against-the-extra-domain-b-for-the-specific-targeting-of-oncofetal-fibronectin/ 2025-06-25T02:30:36+00:00 https://www.palvellatx.com/2025/06/23/schonfeld-d-matschiner-g-chatwell-l-trentmann-s-gille-h-hulsmeyer-m-brown-n-kaye-p-m-schlehuber-s-hohlbaum-a-m-skerra-a-2009-an-engineered-lipocalin-specific-for-ctla/ 2025-06-25T02:30:42+00:00 https://www.palvellatx.com/2025/06/23/klaus-mross-heike-richly-richard-fischer-dirk-scharr-martin-buchert-angelika-stern-hendrik-gille-laurent-p-audoly-max-e-scheulen-2013-first-in-human-phase-i-study-of-prs-050-angiocal-an/ 2025-06-25T02:30:52+00:00 https://www.palvellatx.com/2025/06/23/coby-m-m-laarakkers-erwin-t-wiegerinck-siem-klaver-maria-kolodziejczyk-hendrik-gille-andreas-m-hohlbaum-harold-tjalsma-dorine-w-swinkels-2013-improved-mass-spectrometry-assay-for-plasma/ 2025-06-25T02:31:01+00:00 https://www.palvellatx.com/2025/06/23/olwill-sa-joffroy-c-gille-h-vigna-e-matschiner-g-allersdorfer-a-lunde-bm-jaworski-j-burrows-jf-chiriaco-c-christian-hj-hulsmeyer-m-trentmann-s-jensen-k-hohlbaum-am-audoly-l-2013-a-hi/ 2025-06-25T02:31:11+00:00 https://www.palvellatx.com/2025/06/23/martz-l-2009-designer-lipocalins-scibx-228-8-9-kim-h-j-eichinger-a-skerra-a-2009-high-affinity-recognition-of-lanthanideiii-chelate-complexes-by-a-reprogrammed-human-lipocalin-2-j-am/ 2025-06-25T02:31:18+00:00 https://www.palvellatx.com/2025/06/23/skerra-a-2008-alternative-binding-proteins-anticalins-harnessing-the-structural-plasticity-of-the-lipocalin-ligand-pocket-to-engineer-novel-binding-activities-febs-j-275112677-83/ 2025-06-25T02:31:27+00:00 https://www.palvellatx.com/2025/06/23/breustedt-d-a-schonfeld-d-l-skerra-a-2006-comparative-ligand-binding-analysis-of-ten-human-lipocalins-biochim-biophys-acta-17642-161-173/ 2025-06-25T02:31:37+00:00 https://www.palvellatx.com/2025/06/23/nasreen-a-vogt-m-kim-h-j-eichinger-a-skerra-a-2006-solubility-engineering-and-crystallization-of-human-apolipoprotein-d-protein-sci-151-190-199/ 2025-06-25T02:31:46+00:00 https://www.palvellatx.com/2025/06/23/vopel-s-muhlbach-h-skerra-a-2005-rational-engineering-of-a-fluorescein-binding-anticalin-for-improved-ligand-affinity-biol-chem-38611-1097-1104/ 2025-06-25T02:31:53+00:00 https://www.palvellatx.com/2025/06/23/schlehuber-s-skerra-a-2005-anticalins-in-drug-development-biodrugs-195-279-288/ 2025-06-25T02:32:02+00:00 https://www.palvellatx.com/2025/06/23/schlehuber-s-skerra-a-2005-anticalins-as-an-alternative-to-antibody-technology-expert-opin-biol-ther-511-1453-1462/ 2025-06-25T02:32:10+00:00 https://www.palvellatx.com/2025/06/23/schlehuber-s-skerra-a-2005-lipocalins-in-drug-discovery-from-natural-ligand-binding-proteins-to-anticalins-drug-discov-today-10-23-33/ 2025-06-25T02:32:21+00:00 https://www.palvellatx.com/2025/06/23/breustedt-d-a-korndorfer-i-p-redl-b-crystal-structure-of-human-tear-lipocalin-reveals-an-extended-branched-cavity-with-capacity-for-multiple-ligands-j-biol/ 2025-06-25T02:32:40+00:00 https://www.palvellatx.com/2025/06/23/nygren-p-a-skerra-a-2004-binding-proteins-from-alternative-scaffolds-j-immunol-methods-290-3-28/ 2025-06-25T02:32:48+00:00 https://www.palvellatx.com/2025/06/23/vogt-m-skerra-a-2004-construction-of-an-artificial-receptor-protein-anticalin-based-on-the-human-apolipoprotein-d-chembiochem-5-191-199/ 2025-06-25T02:32:56+00:00 https://www.palvellatx.com/2025/06/23/liu-g-mills-j-l-hess-t-a-kim-s-skalicky-j-j-sukumaran-d-k-kupce-e-skerra-a-szyperski-t-2003-resonance-assignments-for-the-21-kda-engineered-fluorescein-binding-lipocal/ 2025-06-25T02:33:04+00:00 https://www.palvellatx.com/2025/06/23/korndorfer-i-p-beste-g-skerra-a-2003-crystallographic-analysis-of-an-anticalin-with-tailored-specificity-for-fluorescein-reveals-high-structural-plasticity-of-the-lipocalin-loop-region/ 2025-06-25T02:34:13+00:00 https://www.palvellatx.com/2025/06/23/korndorfer-i-p-schlehuber-s-skerra-a-2003-structural-mechanism-of-specific-ligand-recognition-by-a-lipocalin-tailored-for-the-complexation-of-digoxigenin-j-mol-biol-330-385-396/ 2025-06-25T02:34:44+00:00 https://www.palvellatx.com/2025/06/23/gotz-m-hess-s-beste-g-skerra-a-michel-beyerle-m-e-2002-ultrafast-electron-transfer-in-the-complex-between-fluorescein-and-a-cognate-engineered-lipocalin-protein-a-so-called-anticalin/ 2025-06-25T02:34:49+00:00 https://www.palvellatx.com/2025/06/23/schlehuber-s-skerra-a-2002-tuning-ligand-affinity-specificity-and-folding-stability-of-an-engineered-lipocalin-variant-a-so-called-anticalin-using-a-molecular-random-approach-bioph/ 2025-06-25T02:34:55+00:00 https://www.palvellatx.com/2025/06/23/skerra-a-2001-anticalins-a-new-class-of-engineered-ligand-binding-proteins-with-antibody-like-properties-rev-mol-biotechnol-74-257-275/ 2025-06-25T02:35:17+00:00 https://www.palvellatx.com/2025/06/23/schlehuber-s-skerra-a-2001-duocalins-engineered-ligand-binding-proteins-with-dual-specificity-derived-from-the-lipocalin-fold-biol-chem-382-1335-1342/ 2025-06-25T02:35:25+00:00 https://www.palvellatx.com/2025/06/23/schlehuber-s-beste-g-skerra-a-2000-a-novel-type-of-receptor-protein-based-on-the-lipocalin-scaffold-with-specificity-for-digoxigenin-j-mol-biol-297-1105-1120/ 2025-06-25T02:35:32+00:00 https://www.palvellatx.com/2025/06/23/skerra-a-2000-lipocalins-as-a-scaffold-biochim-biophys-acta-1482-337-350/ 2025-06-25T02:35:40+00:00 https://www.palvellatx.com/2025/06/23/skerra-a-2000-engineered-protein-scaffolds-for-molecular-recognition-j-mol-recognit-13-167-187/ 2025-06-25T02:35:48+00:00 https://www.palvellatx.com/2025/06/23/beste-g-schmidt-f-s-stibora-t-skerra-a-1999-small-antibody-like-proteins-with-prescribed-ligand-specificities-derived-from-the-lipocalin-fold-proc-natl-acad-sci-usa-96-1898-1903/ 2025-06-25T02:35:59+00:00 https://www.palvellatx.com/2025/06/23/simultaneous-costimulatory-t-cell-engagement-and-checkpoint-inhibition-by-prs-344-s095012-a-4-1bb-pd-l1-bispecific-compound-for-tumor-localized-activation-of-the-immune-system-aacr-2021/ 2025-06-25T02:36:33+00:00 https://www.palvellatx.com/2025/06/23/marina-pavlidou-janet-peper-lucia-pattarini-christian-barthels-eva-maria-hansbauer-rachida-bel-aiba-milan-blanusa-alix-scholer-dahirel-maximilien-grandclaudon-celine-grand-jamila-elhmouzi-yo/ 2025-06-25T02:36:57+00:00 https://www.palvellatx.com/2025/06/23/marlon-j-hinner-rachida-siham-bel-aiba-corinna-schlosser-thomas-jaquin-andrea-allersdorfer-sven-berger-alexander-wiedenmann-gabriele-matschiner-julia-schuler-ulrich-moebius-christine-rothe/ 2025-06-25T02:37:00+00:00 https://www.palvellatx.com/2025/06/23/lutz-renders-ming-wen-frank-dellanna-heinrichs-sven-klemens-budde-christian-rosenberger-christiane-erley-birgit-bader-claudia-sommerer-schaier-matthias-werner-feuerer-edgar-fenzl-rachel/ 2025-06-25T02:37:06+00:00